SESSION TITLE: COPD Pharmacotherapy
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: Chronic obstructive pulmonary disease (COPD) is a progressive disease that makes it hard to breathe. It is characterized by mucus alterations, airway inflammation and oxidative stress contributing to corticosteroid resistance. Carbocysteine lysine salt monohydrate (CLS) is a mucoactive drug efficacy in the treatment of bronchopulmonary diseases including COPD. The PEACE study showed a reduction of 25% of exacerbations for patients treated with carbocysteine in COPD. However, only 17% of PEACE study patients received background therapy including inhaled steroids (IS).